Author: Trąbka-Zawicki A
The use of mild therapeutic hypothermia (MTH) in patients after out-of-hospital cardiac arrest (OHCA) who are undergoing primary percutaneous coronary intervention (pPCI) can protect patients from thromboembolic complications. The aim of the study was to evaluate the adaptive mechanisms of the coagulation system in MTH-treated comatose OHCA survivors.Twenty one comatose OHCA survivors with acute coronary syndrome undergoing immediate pPCI were treated with MTH. Quantitative and qualitative analyses of physical clot properties were performed using thromboelastography (TEG). Two analysis time points were proposed: 1) during MTH with in vitro rewarming conditions (37oC) and 2) after restoration of normothermia (NT) under normal (37oC) and in vitro cooling conditions (32oC).During MTH compared to NT, reaction time (R) was lengthened, clot kinetic parameter (α) was significantly reduced, but no effect on clot strength (MA) was observed. Finally, the coagulation index (CI) was significantly reduced with clot fibrinolysis attenuated during MTH. The clot lysis time (CLT) was shortened, and clot stability (LY⁶⁰) was lower compared with those values during NT. In vitro cooling generally influenced clot kinetics and reduced clot stability after treatment.Thromboelastography is a useful method for evaluation of coagulation system dysfunction in OHCA survivors undergoing MTH. Coagulation impairment in hypothermia was associated with a reduced rate of clot formation, increased weakness of clot strength, and disturbances of fibrinolysis. Blood sample analyses performed at 32°C during MTH, instead of the standard 37°C, seems to enhance the accuracy of the evaluation of coagulation impairment in hypothermia.
Cardiology journal, [Epub ahead of print]